ReviewPharmacological research2019
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Review in Pharmacological research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 110 citations in OpenAlex.
- An Overview of Rheumatoid Arthritis-Associated Dry Eye Disease, Scleritis, and Peripheral Ulcerative Keratitis.Journal of clinical medicine · 2026Review
- Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways.Biomedicines · 2026Review
- Connection Between Mitochondria and Rheumatoid Arthritis and Osteoarthritis: Personalized Treatment Strategies.Current pharmaceutical design · 2026Review
- Targeting Inflammatory Pathways in Chronic Low Back Pain: Opportunities for Novel Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exosome-like nanovesicles from Peucedanum Japonicum directly regulate inflammatory cytokines via small RNAs.Scientific reports · 2025Article
- Epigenomic landscapes define differential Janus kinases inhibitor sensitivity in IFN-γ-primed human macrophages.iScience · 2025Article
- Synergic effect of combined melatonin and tofacitinib on ameliorating dextran sulfate sodium-induced colitis in rat---role of JAKs/STAT, cell-stress signaling, and inflammatory-immune reaction.American journal of clinical and experimental immunology · 2025Article
- Nano-based Therapeutics for Rheumatoid Arthritis: Recent Patents and Development.Recent patents on nanotechnology · 2025Review
- The JAK-STAT pathway: from structural biology to cytokine engineering.Signal transduction and targeted therapy · 2024Review
- Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).Journal of personalized medicine · 2024Article
- Article
- Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study.BMC rheumatology · 2024Article
- Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Annals of the rheumatic diseases · 2024Review
- Effect of JAK Inhibitors on the Risk of Death in Patients with Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.The Canadian journal of hospital pharmacy · 2024Review
- Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review.Life (Basel, Switzerland) · 2023Review
- Review
- Exploring the Novel Dimension of Immune Interactions in Pain: JAK Inhibitors' Pleiotropic Potential.Life (Basel, Switzerland) · 2023Review
- ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice.Journal of personalized medicine · 2023Article
- In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones.Molecules (Basel, Switzerland) · 2023Article
- Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study.JHEP reports : innovation in hepatology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The past decade has witnessed an explosion in trial data on JAK inhibitors (JAKi). These small molecules target the Janus kinase - signal transducer and activator of transcription (JAK-STAT) pathway, blocking crucial cytokines across a septum of rheumatic diseases. As a class, JAKi are beginning to demonstrate efficacy on par, if not superior to biologics. Two first generation JAKi are licensed for use in inflammatory arthritis; tofacitinib and baricitinib. Next-generation JAKi have been designed with selective affinity for one JAK enzymes, the aim to reduce unwanted adverse effects without declining clinical efficacy. Emerging data with selective JAK1 inhibitors upadacitinib and filgotinib looks very promising. Despite differences in selectivity between JAKi, an overlap exists in their safety profiles. Across the class, a characteristic safety signal is emerging with viral opportunistic infections, particularly herpes zoster. Post marketing drug surveillance will be essential in evaluating the long-term risk with these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.